_Market_-_Cover_Slide.png)
Market Definition
Hepatocellular Carcinoma (HCC) is a liver malignancy that emerges in liver cells and is the sixth most common cancer worldwide. It is the third most cause of cancer-related deaths globally, with prominent risk factors, including excessive alcohol consumption, HBV (Hepatitis B Virus) & HCV (Hepatitis C Virus) infections, and other lifestyle disorders.
Market Insights
The Global Hepatocellular Carcinoma (HCC) Market is projected to grow at a CAGR of around 10.20% during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the increasing instances of liver cancer & rising mortality rates owing to severe lifestyle changes and increasing obesity on account of poor eating habits, coupled with significant investments in research activities associated with the development of advanced therapeutics for HCC.
| Report Coverage | Details |
|---|---|
| Study Period | Historical Data: 2017-20 |
| Base Year: 2021 | |
| Forecast Period: 2022-27 | |
| CAGR | 10.20% |
| Regions Covered | North America: The US, Canada, Mexico |
| Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe | |
| Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific | |
| South America: Brazil, Rest of Latin America | |
| Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa | |
| Key Companies Profiled |
Amgen Inc., AstraZeneca plc, Bayer AG, BeiGene, Bristol Myers Squibb, Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, Pfizer Inc. |
| Unit Denominations | USD Million/Billion |
Moreover, the rapidly surging clinical trials for HCC drugs & medications by the leading biotech & pharma companies are further creating lucrative prospects for the global market through 2027. FDA, PMDA, & EMA, among other regulatory agencies worldwide, are offering significant incentives to biopharma companies for developing orphan drugs for rare diseases while also providing fast drug approvals. For instance:
With the FDA approval of Avastin (bevacizumab) and Tecentriq (atezolizumab) as the first-line HCC treatment, healthcare R&D has been focusing extensively on developing more effective and affordable combination therapies.
Combinations of PD- 1 or PDL- 1 with multikinase inhibitors, anti-VEGF drugs, or CTLA- 4 inhibitors are already well represented in late-stage HCC. As a result, the rising cases of liver cancer worldwide are creating numerous opportunities for these medications, which, in turn, would expand the global market in the years to come.
However, adverse effects like skin & gastrointestinal disorders, fatigue, hair loss, etc., in many patients suffering from HCC due to high drug dosage, coupled with the unavailability of HCC diagnoses & treatments in rural areas, are a few aspects projected to hinder the growth of the Global Hepatocellular Carcinoma (HCC) Market through 2027.
_Market-_Segmentation.png)